In androgen-independent prostate cancers expressing both AR and the “undruggable” truncation variant AR-V7, where AR antagonists inhibit only ~40% of AR activity...
Our AR/AR-V7 TRACER, which links an AR SARM to an MBD2 recruiter, suppresses more than 90% of AR transcriptional activity.